Trials commence on consortium's fully personalized cancer vaccines for glioblastoma

14 October 2014

A consortium funded by the European Union is to advance a new class of fully personalized cancer vaccines into clinical trials for brain cancer. German therapeutic and biomarker-based diagnostics company BioNTech and privately-owned oncology biotech specialist immatics are now moving glioma actively personalized vaccine consortium (GAPVAC) into the clinic.

The German national authority has approved each individual patient based on the specific characteristics of their tumor and immune system, and screening of the first trial participants has commenced at the University Hospital in Heidelberg and the University Hospital in Tuebingen. The manufacturing process will be performed by the good manufacturing practice unit of the University of Tuebingen.

Personalized vaccine for glioblastoma

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK